Global Duchenne Muscular Dystrophy (DMD) Market By Diagnosis (Enzyme Tests, Blood test, Genetic Testing, Muscle biopsy, CT Scan, Electromyogram (EMG), Electrocardiogram (ECG or EKG), Others); By Stages (Early Ambulatory, Late Ambulatory, Early Non-Ambulatory, Late Non-Ambulatory); By Clinical Phase (Pre-clinical, Phase 1, Phase 2, Phase 3, Phase 4, Approval); By Age Group (1 to 4 years, 5 to 7 years, 8 to 11 years, 12 to 19 years, Adults); By Treatment (Medication – Corticosteroids, Heart medications, Therapy – Range-of-motion and stretching exercises, Braces, Mobility aids, Breathing assistance, Others, Surgery, Diet and Nutritional supplements, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1385 | Category : Healthcare | Published Date : January, 2023 | Pages : 402 | Format :PDF